Biostem Technologies Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OID
Vurst Andrew Smith-Van, Chief Operating Officer, a Director and 10% owner of Biostem Technologies, reported multiple transactions in common stock on September 15, 2026.
OID
Jason Matuszewski, Chief Executive Officer, a Director and 10% owner of Biostem Technologies, reported multiple transactions in common stock on September 15, 2026.
OID
Kenneth Howard Warrington Jr, a Director of Biostem Technologies, reported multiple transactions in common stock on September 15, 2026.
OID
Michael A Fortunato, Chief Accounting Officer of Biostem Technologies, reported multiple transactions in common stock on September 15, 2026.
OID
Barry Hassett, Chief Commercial Officer of Biostem Technologies, reported multiple transactions in common stock on September 9, 2026.
OID
Jodi Ungrodt, a Director of Biostem Technologies, reported multiple transactions in common stock on August 27, 2026.
OID
Mark A Glickman, a Director of Biostem Technologies, reported multiple transactions in common stock on August 27, 2026.
OID
Hannaway Rayna Lesser, a Director of Biostem Technologies, reported multiple transactions in common stock on August 27, 2026.
OID
Kenneth Howard Warrington Jr, a Director of Biostem Technologies, reported multiple transactions in common stock on August 27, 2026.
OID
Steven D Sonenreich, a Director of Biostem Technologies, reported multiple transactions in common stock on August 27, 2026.
OID
Brandon Poe, Chief Financial Officer of Biostem Technologies, reported multiple transactions in common stock on August 11, 2026.
OID
Michael A Fortunato, Chief Accounting Officer of Biostem Technologies, reported multiple transactions in common stock on August 9, 2026.